In pancreatic cancer, a phase III study (POLO) of PARPi, olaparib, in the maintenance setting after response to platinum-based chemotherapy in patients with germline BRCA1/2 mutation carriers demonstrated a significant improvement in PFS compared to a placebo (7.4 months vs. 3.8 months, respectively; HR 0.53; 95% CI, 0.35 to 0.82; p = 0.0038) with no significant difference in the change in global quality of life score [34,35]. Here, BRCA1 is linked to familial pancreatic carcinoma.